Cargando…

Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection

Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zheng, Li, Ying, Ma, Yuanhui, Zhang, Heng, Deng, Yunfeng, Zhu, Zuobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241766/
https://www.ncbi.nlm.nih.gov/pubmed/34220307
http://dx.doi.org/10.7150/ijms.58742
_version_ 1783715483158052864
author Zhou, Zheng
Li, Ying
Ma, Yuanhui
Zhang, Heng
Deng, Yunfeng
Zhu, Zuobin
author_facet Zhou, Zheng
Li, Ying
Ma, Yuanhui
Zhang, Heng
Deng, Yunfeng
Zhu, Zuobin
author_sort Zhou, Zheng
collection PubMed
description Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). Thus, it is very important to effectively predict which patients with mild disease are more likely to progress to severe disease. A total of 72 patients hospitalized with COVID-19 in Shandong Provincial Public Health Clinical Center and 1141 patients included in the published papers were enrolled in this study. We determined that the combination of interleukin-6 (IL-6), Neutrophil (NEUT), and Natural Killer (NK) cells had the highest prediction accuracy (with 75% sensitivity and 95% specificity) for progression of COVID-19 infection. A binomial regression equation that accounted for a multiple risk score for the combination of IL-6, NEUT, and NK was also established. The multiple risk score is a good indicator for early stratification of mild patients into risk categories, which is very important for adjusting the treatment plan and preventing death.
format Online
Article
Text
id pubmed-8241766
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-82417662021-07-01 Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection Zhou, Zheng Li, Ying Ma, Yuanhui Zhang, Heng Deng, Yunfeng Zhu, Zuobin Int J Med Sci Research Paper Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). Thus, it is very important to effectively predict which patients with mild disease are more likely to progress to severe disease. A total of 72 patients hospitalized with COVID-19 in Shandong Provincial Public Health Clinical Center and 1141 patients included in the published papers were enrolled in this study. We determined that the combination of interleukin-6 (IL-6), Neutrophil (NEUT), and Natural Killer (NK) cells had the highest prediction accuracy (with 75% sensitivity and 95% specificity) for progression of COVID-19 infection. A binomial regression equation that accounted for a multiple risk score for the combination of IL-6, NEUT, and NK was also established. The multiple risk score is a good indicator for early stratification of mild patients into risk categories, which is very important for adjusting the treatment plan and preventing death. Ivyspring International Publisher 2021-05-27 /pmc/articles/PMC8241766/ /pubmed/34220307 http://dx.doi.org/10.7150/ijms.58742 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhou, Zheng
Li, Ying
Ma, Yuanhui
Zhang, Heng
Deng, Yunfeng
Zhu, Zuobin
Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title_full Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title_fullStr Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title_full_unstemmed Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title_short Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
title_sort multi-biomarker is an early-stage predictor for progression of coronavirus disease 2019 (covid-19) infection
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241766/
https://www.ncbi.nlm.nih.gov/pubmed/34220307
http://dx.doi.org/10.7150/ijms.58742
work_keys_str_mv AT zhouzheng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection
AT liying multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection
AT mayuanhui multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection
AT zhangheng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection
AT dengyunfeng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection
AT zhuzuobin multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection